Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago / Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models

RICHMOND HILL, ONTARIO -- (Marketwired) -- 02/06/18 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative ...

Original Article: Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago / Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models

More From BioPortfolio on "Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago / Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models"